Impacts of Black Box Warning, National Coverage Determination, and Risk Evaluation and Mitigation Strategies on the Inpatient On-Label and Off-Label Use of Erythropoiesis-Stimulating Agents

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.614
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Methylphenidate Off-Label Use and Safety

SpringerPlus
Multidisciplinary
2014English

Search Strategies to Identify Reports on “Off-Label” Drug Use in EMBASE

BMC Medical Research Methodology
EpidemiologyHealth Informatics
2012English

Reasons for and Frequency of Off - Label Drug Use

Medicinski Pregled
Medicine
2015English

The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Innovation and Off‐label Use, the French Case and More

British Journal of Clinical Pharmacology
Pharmacology
2019English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Warning Label Placement: The Difference Effect of Social Risk and Health Risk Consequences

European Research Studies Journal
ManagementFinanceBusinessEconomicsAccountingEconometrics
2019English

«Off Label Use»: Nouvelles Recommandations

Bulletin des Médecins Suisses
2007English

Off-Label Use of Medicinal Products - Legal Rules and Practices

Acta Poloniae Pharmaceutica
PharmacologyPharmaceutical Science
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy